Company BrightPath Biotherapeutics Co., Ltd.

Equities

4594

JP3274140007

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Other Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-14 am EDT			5-day change	1st Jan Change
58 ^JPY	+1.75%		-1.69%	-33.33%

2023	BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	CI
2023	BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	CI

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

Number of employees: 42

JPY in Million	2022	Weight	2023	Weight	Delta
Other 94.7 %	15	97.4 %	5	94.7 %	-66.67%
Research and Development 5.3 %	0	2.6 %	0	5.3 %	-31.37%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	15	100.0 %	5	100.0 %	-65.73%

Managers	Title	Age	Since
Kenichi Nagai CEO	Chief Executive Officer	54	08-12-31
Norihiro Nakamura BRD	Director/Board Member	55	16-04-30

Members of the board	Title	Age	Since
Hirotaka Takeuchi BRD	Director/Board Member	77	15-05-31
Akira Yamada BRD	Director/Board Member	67	03-04-30
Kenichi Nagai CEO	Chief Executive Officer	54	08-12-31
Norihiro Nakamura BRD	Director/Board Member	55	16-04-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	70,941,300	67,769,399 ( 95.53 %)	1 ( 0.000001 %)	95.53 %

Name	Equities	%	Valuation
Mitsubishi UFJ Capital Co., Ltd. 0.6361 %	450,000	0.6361 %	171 576 ¥
Hiroshi Akeo 0.6361 %	450,000	0.6361 %	171 576 ¥
Akira Nishimura 0.5089 %	360,000	0.5089 %	137 261 ¥
Kazuhiko Kaneko 0.5023 %	355,300	0.5023 %	135 469 ¥
Takehiko Nakazato 0.4948 %	350,000	0.4948 %	133 448 ¥
Toshiaki Kazura 0.4625 %	327,200	0.4625 %	124 755 ¥
Kenichi Nagai 0.3393 %	240,000	0.3393 %	91 507 ¥
Akira Yamada 0.2615 %	185,000	0.2615 %	70 537 ¥
THE CHIKUHO BANK, LTD. 0.0707 %	50,000	0.0707 %	19 064 ¥
SPARX Asset Management Co., Ltd. 0.0471 %	33,300	0.0471 %	12 697 ¥

BrightPath Biotherapeutics Co., Ltd.

Life Innovation Center, 412 3-25-22 Tono-machi

210-0821, Kanagawa

http://www.brightpathbio.com

address BrightPath Biotherapeutics Co., Ltd.(4594)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRIGHTPATH BIOTHERAPEUTICS CO., LTD.	-33.33%	25.81M
MODERNA, INC.	+26.37%	48.16B
IQVIA HOLDINGS INC.	-1.01%	41.73B
LONZA GROUP AG	+45.09%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+9.34%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	18.96B
BIO-TECHNE CORPORATION	+6.23%	12.92B
MEDPACE HOLDINGS, INC.	+26.99%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.77B

Other Biotechnology & Medical Research